HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women's health study.

Abstract
Chronic inflammation has been implicated in the etiology of gastric cancer. Prostaglandin E(2) (PGE(2)) is one of the major end-products of the cyclooxygenase-2 pathway, an enzyme that is an important mediator of inflammation. Using a novel method of quantifying the primary urinary metabolite of PGE(2) (PGE-M; 11alpha-hydroxy-9,15-dioxo-2,3,4,5-tetranorprostane-1,20-dioic acid), we evaluated urinary PGE-M concentrations in association with subsequent risk of development of gastric cancer in the Shanghai Women's Health Study, a large population-based prospective cohort, using a nested case-control study design. Controls were matched (1:1) to 153 gastric cancer cases by menopausal status; age, time, and date of sample collection; time interval since last meal; and availability of urine sample. Odds ratios (95% confidence intervals) were calculated using conditional logistic regression adjusted for potential confounders. Baseline urinary PGE-M levels were slightly higher among gastric cancer cases with a median of 6.4 ng/mg creatinine (interquartile range, 3.4-11.2) compared with 5.4 ng/mg creatinine among controls (interquartile range, 2.8-9.0), but this difference was not statistically significant (P = 0.34, Wilcoxon). With increasing quartiles of urinary PGE-M levels, the odds ratios (95% confidence intervals) for risk of gastric cancer increased in quartiles 2 to 4: 1.00 (0.48-2.08), 1.40 (0.67-2.91), and 1.98 (0.95-4.13), with a statistically significant test for trend (P = 0.04). The association persisted after additional adjustment for Helicobacter pylori status and was slightly strengthened among non-nonsteroidal anti-inflammatory drug users, subjects with positive H. pylori status, and for cases diagnosed within 46 months after study enrollment. Our findings suggest that higher levels of urinary PGE-M, a marker of inflammation, may be associated with gastric cancer risk.
AuthorsLinda M Dong, Xiao-Ou Shu, Yu-Tang Gao, Ginger Milne, Bu-Tian Ji, Gong Yang, Hong-Lan Li, Nathaniel Rothman, Wei Zheng, Wong-Ho Chow, Christian C Abnet
JournalCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (Cancer Epidemiol Biomarkers Prev) Vol. 18 Issue 11 Pg. 3075-8 (Nov 2009) ISSN: 1538-7755 [Electronic] United States
PMID19861525 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural)
Chemical References
  • Biomarkers, Tumor
  • Prostaglandins
  • 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid
Topics
  • Adult
  • Aged
  • Biomarkers, Tumor (urine)
  • Case-Control Studies
  • China
  • Cohort Studies
  • Female
  • Helicobacter Infections (pathology, surgery, urine)
  • Helicobacter pylori (genetics)
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Prospective Studies
  • Prostaglandins (urine)
  • Risk Factors
  • Stomach Neoplasms (pathology, surgery, urine)
  • Women's Health

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: